PCOS Is Renamed PMOS: What You Need to Know
Polycystic ovary syndrome (PCOS)—a hormonal disorder that affects about 10% of reproductive-aged women worldwide—is being renamed polyendocrine metabolic ovarian syndrome (PMOS), according to an international expert consensus published in The Lancet in May 2026.
The new name is meant to better reflect the condition’s full-body impact. But patients should not expect immediate changes to their diagnosis or treatment. Adoption of the new name will take time.
“This is the beginning of steps in the right direction,” says Lubna Pal, MBBS (a medical degree awarded outside of the U.S.), MS, a reproductive endocrinologist at Yale Medicine who contributed to surveys informing the effort.
Dr. Pal describes the shift as moving from a “microscopic” to a “telescopic” view.
“This is about changing our lens. This condition has multidimensional implications,” Dr. Pal says, explaining that the condition is linked to a range of effects, including menstrual and ovulatory dysfunction, psychological burden and metabolic havoc, and long-term health risks such as diabetes and cardiovascular disease. “One of the reasons for the switch in terminology is to move away from classifying it as a reproductive disorder.”
Why is PCOS being renamed?
The original name, PCOS, has long been considered misleading by specialists. It focuses attention on cysts in the ovaries, which are not always present and are not the defining feature of the condition.
“The label has been doing a disservice,” Dr. Pal says. “It conveys that the problem is all in the ovary.”
In reality, the condition involves multiple systems across the body. It may present with symptoms such as irregular periods, elevated androgen (male hormone) levels, and fertility difficulty, but also insulin resistance, increased long-term risk of type 2 diabetes, and abnormal cholesterol levels.
How the condition presents varies significantly from person to person. That variation is one reason experts say the previous name fell short—it pointed to one feature of a condition that can look very different across patients.
What the name change does—and doesn’t do
Despite headlines about the name change, patients should know that their diagnosis has not changed.
The published consensus marks an important shift in how specialists conceptualize the condition—but it does not immediately change diagnostic criteria, treatment guidelines, or clinical terminology in most settings. Patients should expect to see PCOS on insurance forms, medical records, and prescriptions for the foreseeable future.
Experts emphasize that adoption of the term PMOS will take time, and key questions—such as whether current diagnostic criteria fully reflect the condition—remain under review.
“The work lies ahead,” Dr. Pal says.
She notes that not all patients have the same metabolic risks or underlying drivers, underscoring the need for more individualized care. What is changing, she says, is how clinicians and patients are encouraged to think about it. The new name is meant to shift attention toward the interplay of multiple systems that influence long-term health.
Why does the name matter?
The renaming is not just a semantic update. Specialists hope it will shift how patients—and clinicians—think about long-term care.
“The ramifications continue across the lifespan,” Dr. Pal says, noting that some symptoms—such as irregular periods—may become less noticeable with age, even as underlying metabolic risks persist. “Patients can fall off the radar, while their metabolic underpinnings worsen.”
That pattern is a clinical concern. A patient who no longer experiences obvious reproductive symptoms may stop seeking regular care, but the condition still requires monitoring.
The new framing is intended to encourage ongoing attention to overall health—not just fertility or cycle regularity. “The goal is not to fix the label,” she says, “but to optimize the patient’s well-being.”
Ultimately, the name change is intended to reflect the entirety of the condition, with the idea that care should follow patients over time. If you have been diagnosed with PCOS, no immediate action is required in response to the name change. Your diagnosis remains valid.
If you have concerns about whether your care addresses the full picture—including metabolic factors such as blood sugar, cholesterol, or cardiovascular risk—it is worth raising those with your doctor. People with PMOS benefit from care that looks beyond any single symptom.
“It’s like a hand-wound watch with an intricate system of interconnected cogs and gears. A turn of a single cog sets a ripple of motion through the rest,” Dr. Pal says. “We have to figure out which part is driving the dysfunction—not just keep winding it.”
